A global leader in industrial vision systems and inspection machines, Antares Vision Group was founded in 2007 as an innovative start-up. Since then, it has secured ever-growing shares of the market year after year, in different sectors, with applications ranging from biomedical devices, hospital services, and food and beverages to cosmetics, chemicals, and packaging. Through the integrated management of production and supply chain data, the application of AI, and the use of blockchain technology, Antares Vision offers the market an integrated ecosystem of technologies, software, and hardware for product quality control. An achievement driven by inspection systems and machines that also guarantee traceability along the entire supply chain, from raw materials to production and distribution, through to the consumer. Gianfranco Landolfi, General Manager for life science & cosmetics in Antares Vision Group, talked to us about it.
“Pharmintech is a key event for us,” Mr Landolfi began. “It takes place in Italy, which is not only home to the Antares Vision Group headquarters, but also one of the most dynamic hubs in the global pharmaceuticals industry. Our country is attracting growing investments from major international groups, confirming its role as a major pharmaceuticals hub in Europe. Today, we are witnessing a new drive towards ensuring compliance with the Falsified Medicines Directive (FMD), not so much by large companies - whose production for export means they have been compliant for some time now - but by smaller companies or operators, such as parallel importers, who now have to adapt to the legislation. In this scenario, our solutions are scalable and also accessible to less structured companies, and they can provide reliability and efficiency with even a modest, sustainable investment. Finally, Pharmintech is also a gateway to new strategic markets, such as those of the Mediterranean basin and the Middle East, where we are seeing excellent opportunities for growth.”
“At Pharmintech we will be showcasing Inspecta, our new suite for on-line visual inspections.” Mr Landolfi continued, “It is a highly modular and scalable system, which is designed to cater to current requirements and adapt to future needs. We have focussed heavily on the user interface and configuration speed, to make the user experience even smoother and more efficient. We will also be presenting our new Pin Hole Detector, in addition to the latest evolution of our AI powered BFC system, which strengthens inspections on blister machines through enhanced performance. On the AI front, our partnership with subsidiary Orobix has generated some very real - and in some cases already operational - solutions. One of these is the Smart Clearance feature, which automates and optimises the line clearance process and is already incorporated into our All-in-One machine. Another new solution, Predictive Maintenance, can be applied to both our systems and those offered by other firms and enables users to predict failures and optimise maintenance, resulting in less downtime.
Finally, also on display at our stand will be a sophisticated machine for the inspection of pre-filled syringes (PFS). We will be providing demonstrations of the equipment, which features quality controls targeting various critical points of the syringes, including the finger grip and the stopper, and an innovative AI-based system for needle shield inspection, filling level control, and double particle control, to detect contaminants in both the liquid and the container.”
“We are witnessing a strengthening of the role of contract manufacturing organisations, to which market authorisation holders are outsourcing increasingly complex activities,” Mr Landolfi continued. “This means there is a growing demand for flexibility, both on the lines - to manage frequent changeovers and small batches - and in terms of communication between levels L3 and L4, often in hybrid architectures. Another key trend we are seeing emerge is digitalisation. No longer just about compliance, digitalisation has become a strategic tool for enhancing data, streamlining processes, accelerating decisions, and connecting the entire supply chain to the end patient. Another trend, ePI (electronic Product Information), also fits perfectly into this scenario, making information more accessible, updatable, and sustainable. But the developments extend even further: we are seeing growing integration between PFS and the patient, through connected digital solutions that revolutionise treatment - especially in cases of home administration for chronic diseases - through the introduction of reminders, traceability, treatment adherence, and connection with clinical facilities. To tackle these new challenges, we are designing and developing hardware and software that can be quickly and easily adapted and integrated, even within complex ecosystems.”
“Digitalisation is a consolidated trend and also a catalyst for sustainability,” concluded Gianfranco Landolfi. “Through data analysis and intelligent data use, users can improve process efficiency, reduce waste, and curb operating and energy costs, with knock-on benefits for their finances and the environment. With this in mind, Antares Vision Group - pioneer in traceability and now a leader in full stack solutions (from level L1 to L4) - has developed DIAMIND. An integrated, modular ecosystem of solutions, Diamind connects technologies to enable a data-driven path to digital innovation that manages traceable data and production processes, in order to guarantee end-to-end sustainability, complete traceability, and the direct involvement of end customers. Among the specific solutions, we will be showcasing Cold Chain, our technology offering for real-time monitoring of the cold chain in the distribution of heat-sensitive drugs, such as vaccines and biological drugs, whose sales are soaring.”
.png)
.png)
.png)
